Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 310 participants.

Also called NCT01448174

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose basic science
Phase
Phase 4
Enrolled
  • 310 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01448174
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01448174. Randomized; double masking; primary purpose basic science. Start 2011-10 (registry gives no type); primary completion 2014-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients
Condition
Renal Failure Chronic Requiring Hemodialysis
Condition
Diabetes Mellitus Type 2
Condition
Hyperlipidemia
Intervention (Drug)
Atorvastatin
Lead sponsor
Poznan University of Medical Sciences (class: other)

Record details

Record id
cardio:ct-nct01448174
Content hash
a1db61aac8be51bec6b5791b0fc3e1bb7735d0d9256e1a60feccc9337e1ad32d